Alice S. Mims

Oncology
410 W 10th Ave
Columbus, OH 43210

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 138 publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Journal: The New England journal of medicine
Published: September 02, 2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Journal: Blood
Published: May 04, 2026

RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

Journal: Blood cancer discovery
Published: May 01, 2026

RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma.

Journal: Blood cancer discovery
Published: May 01, 2026

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Journal: Leukemia & lymphoma
Published: April 09, 2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Journal: American journal of hematology
Published: April 02, 2026

Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma.

Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma.

Journal: bioRxiv : the preprint server for biology
Published: January 23, 2026

Concomitant or sequential lower intensity triplet therapy in AML.

Concomitant or sequential lower intensity triplet therapy in AML.

Journal: The Lancet. Haematology
Published: November 21, 2025

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report.

Journal: Blood advances
Published: November 19, 2025

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Journal: Blood advances
Published: November 19, 2025

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial.

Journal: Cancers
Published: November 03, 2025
Showing 1-12 of 138

Last Updated: 09/26/2026